See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/6538897

Metal Triflate Catalyzed Reactions of Alkenes, NBS, Nitriles, and TMSN3: Synthesis of 1,5-Disubstituted Tetrazoles

ARTICLE *in* THE JOURNAL OF ORGANIC CHEMISTRY · APRIL 2007

Impact Factor: 4.72 · DOI: 10.1021/jo062432j · Source: PubMed

CITATIONS READS 71

3 AUTHORS, INCLUDING:



Saumen Hajra IIT Kharagpur

52 PUBLICATIONS **608** CITATIONS

SEE PROFILE



Debarshi Sinha

Indian Institute of Science Education and Re...

18 PUBLICATIONS 189 CITATIONS

SEE PROFILE



Metal Triflate Catalyzed Reactions of Alkenes, NBS, Nitriles, and TMSN₃: Synthesis of 1,5-Disubstituted Tetrazoles

Saumen Hajra,* Debarshi Sinha, and Manishabrata Bhowmick

Department of Chemistry, Indian Institute of Technology, Kharagpur 721 302, India

shajra@chem.iitkgp.ernet.in

Received November 27, 2006

$$R^{1} \xrightarrow{R^{2}} \frac{M(OTf)_{n} (5 \text{ mol}\%), \text{ NBS } (1.2 \text{ equiv})}{TMSN_{3} (1.5 \text{ equiv})} \xrightarrow{R^{3} \text{ NNN}} R^{3} = \text{ alkyl, aryl}, H$$

$$R^{3} = \text{ alkyl, aryl}$$

$$R^{3} = \text{ lkyl, aryl}$$

A versatile and highly efficient protocol for the synthesis of 1,5-disubstituted tetrazoles has been developed by metal triflate catalyzed one-pot reaction of alkenes, NBS, nitriles, and TMSN₃. Among the metal triflates, $Zn(OTf)_2$ was found to be the best catalyst. Use of different combinations of alkenes and nitriles generate a variety of 1,5-disubstituted tetrazoles containing an additional α -bromo functionality of the N1-alkyl substituent.

Tetrazoles are increasingly important heterocyclic compounds in medicinal chemistry. ¹ 5-Substituted 1*H*- and 1,5-disubstituted tetrazoles are often used as metabolically stable surrogates for the carboxylic acid group and for the *cis*-amide bond, respectively. ²⁻⁴ An enormous number of tetrazole-containing biologically active compounds are known in the literature. ^{5,6}

Recently, 1-benzyl-5-aryltetrazoles were found to be novel antagonists for the P2X₇ receptor.⁷

In the literature, 1*H*-tetrazoles⁸ and polycyclic fused tetrazoles^{6b,9} are mostly prepared by inter- and intramolecular [3 + 2]-cycloaddition, respectively, of azides and nitriles. 1,5-Disubstituted tetrazoles are usually obtained from secondary amides or thioamides on reaction with PCl₅/HN₃,³ TMSN₃/Ph₃P/DEAD,¹⁰ and TMSN₃/Et₃N/Hg(II),¹¹ mostly under noncatalytic conditions. Hassner reported AgClO₄-promoted reaction of alkenes, halogens (Br2 or I2), nitriles, and NaN3, noting the ability to produce the 1,5-disubstituted tetrazoles. 12 Many methods for the synthesis of tetrazoles are known, but due to their importance, the development of new synthetic approaches using mild reaction conditions remains an active research area. In this paper, we describe a metal triflate catalyzed one-pot reaction of alkenes, N-bromosuccinimide (NBS), nitriles, and trimethylsilyl azide (TMSN₃) for the expedient synthesis of 1,5-disubstituted tetrazoles containing an additional α-bromo functionality of the N1-alkyl substituent that might provide a further avenue for structural elaboration.

We are involved in stereoselective 1,2-halo functionalization of alkenes and recently found that Lewis acids, in particular, metal triflates, activate NBS to facilitate the formation of halonium ions from alkenes. ¹³ Accordingly, we anticipated that a suitable metal triflate might catalyze the reaction of alkenes, NBS, nitriles, and TMSN₃ and that would produce the 1,5-

(6) (a) May, B. C. H.; Abell, A. D. J. Chem. Soc., Perkin. Trans. 1 2002, 172–178. (b) Davis, B.; Brandstetter, T. W.; Smith, C.; Hackett, L.; Winchester, B. G.; Fleet, G. W. J. Tetrahedron Lett. 1995, 36, 7507–7510. (c) Brandstetter, T. W.; Davis, B.; Hyestt, D.; Smith, C.; Hackett, L.; Winchester, B. G.; Fleet, G. W. J. Tetrahedron Lett. 1995, 36, 7511–7514. (d) Zabrocki, J.; Smith, D.; Dunbar, J. B., Jr.; Marshall, K. W.; Toth, M. V.; Marshall, G. R. J. Org. Chem. 1992, 57, 202–209. (e) Ermert, P.; Vasella, A. Helv. Chim. Acta 1991, 74, 2043. (f) Lebl, M.; Slaninova, J.; Johnson, R. L. Int. J. Pept. Protein Res. 1990, 33, 16. (g) Poonian, M. S.; Nowoswiat, E. F.; Blount, J. F.; Williams, T. H.; Pitcher, R. G.; Kramer, M. J. J. Med. Chem. 1976, 19, 286–290. (h) Poonian, M. S.; Nowoswiat, E. F.; Blount, J. F.; Kramer, M. J. J. Med. Chem. 1976, 19, 1017–1020. (i) Herbst, R. M.; Froberger, C. F. J. Org. Chem. 1957, 22, 1050–1053. (7) Nelso, D. W.; Greg, R. J.; Kort, M. E.; Perez-Medrano, A.; Voight,

(7) Nelso, D. W.; Greg, R. J.; Kort, M. E.; Perez-Medrano, A.; Voight, E. A. Wang, Y.; Grayson, G.; Namvic, M. T.; Donnelly-Roberts, D. L.; Nifratos, W.; Honore, P.; Jarvis, M. F.; Faltynek, C. R.; Carroll, W. A. *J. Med. Chem.* **2006**, *49*, 3659–3666.

(8) (a) Kivrakidou, O.; Brase, S.; Hulshorst, F.; Griebenow, N. Org. Lett. **2004**, *6*, 1143–1146. (b) Demko, Z.; Sharpless, K. B. Org. Lett. **2002**, *4*, 2525–2527. (c) Demko, Z.; Sharpless, K. B. J. Org. Chem. **2001**, *66*, 7945–7950. (d) Alterman, M.; Hallberg, A. J. Org. Chem. **2000**, *65*, 7984–7989. (e) Wittenberger, S. J.; Donner, B. G. J. Org. Chem. **1993**, *58*, 4139–4141. (f) Garbrecht, W. L.; Herbst, R. M. J. Org. Chem. **1953**, *18*, 1269–1282. (g) Herbst, R. M.; Roberts, C. W.; Harvill, E. J. J. Org. Chem. **1951**, *16*, 139–149.

(9) (a) Couty, F.; Durrat, F.; Prim, D. *Tetrahedron Lett.* **2004**, *45*, 3725–3728. (b) Demko, Z.; Sharpless, K. B. *Org. Lett.* **2001**, *3*, 4091–4094. (c) Porter, T. C.; Smalley, R. K.; Teguiche, M.; Purwoo, B. *Synthesis* **1997**, *7*, 773–777. (d) Garanti, L.; Zecchi, G. *J. Org. Chem.* **1980**, *45*, 4767–4769.

(10) (a) Duncia, J. V.; Pierce, M. E. Santella, J. B., III. *J. Org. Chem.* **1991**, *56*, 2395–2400. (b) Athanassopoulos, C. M.; Garnelis, T.; Vahliotis, D.; Papaioannou, D. *Org. Lett.* **2005**, *7*, 561–564.

(11) (a) Pandey, N.; Meyyappan, M.; Vasella, A. *Helv. Chim. Acta* **2000**, *83*, 513–538. (b) Batey, R. A.; Powell, D. A. *Org. Lett.* **2000**, *2*, 3237–3240.

(12) Hassner, A.; Levy, L. A.; Gault, R. *Tetrahedron Lett.* **1966**, *7*, 3119–3123.

(13) (a) Hajra, S.; Bhowmick, M.; Karmakar, A. *Tetrahedron Lett.* **2005**, 46, 3073–3077. (b) Hajra, S.; Maji, B.; Karmakar, A. *Tetrahedron Lett.* **2005**, 46, 8599–8603. (c) Hajra, S.; Sinha, D.; Bhowmick, M. *Tetrahedron Lett.* **2006**, 47, 7017–7019. (d) Hajra, S.; Sinha, D.; Bhowmick, M. *J. Org. Chem.* **2006**, 71, 9237–9240.

^{(1) (}a) Moderhack, D. *J. Prakt. Chem.* **1998**, *340*, 687–709. (b) Butler, R. N. In *Comprehensive Heterocyclic Chemistry II*; Katritzky, A. R., Rees, C. W., Scriven, E. F. V., Eds.; Pergamon Press: New York, 1996; Vol. 4, pp 621–678. (c) Wittenberger, S. J. *Org. Prep. Proced. Int.* **1994**, *26*, 499–531. (d) Butler, R. N. In *Comprehensive Heterocyclic Chemistry*; Potts, K. T., Ed.; Pergamon Press: New York, 1984; Vol. 5, pp 791–838.

⁽²⁾ Herr, R. J. *Bioorg. Med. Chem.* **2002**, *10*, 3379—3393 and references therein.

⁽³⁾ Yu, K. L.; Johnson, R. L. J. Org. Chem. 1987, 52, 2051–2059.
(4) Zabrocki, J.; Smith, D.; Dunbar, J. B., Jr.; Iijima, H.; Marshall,

⁽⁴⁾ Zabrocki, J.; Smith, D.; Dunbar, J. B., Jr.; Iijima, H.; Marshal G. R. J. Am. Chem. Soc. 1988, 110, 5875-5880.

^{(5) (}a) Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Predergast, K.; Smith, R. D.; Timmermans, P. B. M. W. M. J. Med. Chem. 1996, 39, 625–656. (b) Bondensgaard, K.; Ankersen, M.; Thogersen, H.; Hansen, B. S.; Wulf, B. S.; Bywater, R. P. J. Med. Chem. 2004, 47, 888–899. (c) Kozikowski, A. P.; Zhang, J.; Nan, F.; Petukhov, P. A.; Grajkowaska, E.; Wroblewski, J. T.; Yamamoto, T.; Bzdega, T.; Wroblewska, B.; Neale, J. H. J. Med. Chem. 2004, 47, 1729–1738. (d) Burg, D.; Hameetman, L.; Filippov, D. V.; van der Marel, G. A.; Mulder, G. J. Bioorg. Med. Chem. Lett. 2002, 12, 1579–1582. (e) De Lombaert, S.; Blanchard, L.; Stamford, L. B.; Tan, J.; Wallace, E. M.; Satoh, Y.; Fitt, J.; Hoyer, D.; Simonsbergen, D.; Moliterni, J.; Marcopoulos, N.; Savage, P.; Chou, M.; Trapani, A. J.; Jeng, A. Y. J. Med. Chem. 2000, 43, 488–504. (f) De Lombaert, S.; Blanchard, L.; Tan, J.; Sakane, Y.; Bery, C.; Ghai, R. D. Bioorg. Med. Chem. Lett. 1995, 5, 145–150.

TABLE 1. Screening of Metal Triflates as Catalysts for the Reaction of 1a with NBS, Acetonitrile, and TMSN₃

entry	ML_n	t (h)	2a/3a ^a	yield of $2a^b$ (%)
1	none	12	50:50°	20
2	La(OTf) ₃	10	78:22	70
3	$Yb(OTf)_3$	5	80:20	73
4	$Y(OTf)_3$	1	>95:05	82
5	$Sm(OTf)_3$	1	>95:05	84
6	$In(OTf)_3$	1	>95:05	70
7	$Zn(OTf)_2$	10 min	>95:05	87

 a Determined from 1 H NMR analysis of the crude reaction mixture. b Isolated yield of pure ${\bf 2a}$ after column chromatography. c Along with an equal amount of ${\bf 4a}$.

disubstituted tetrazoles along the lines of the Hassner method. ¹² In searching for an effective catalyst, we initiated the reaction of styrene with NBS, acetonitrile, and TMSN₃ in the presence of different Lewis acids, in particular, metal triflates (Table 1). Among the metal triflates studied, Zn(OTf)₂ was found to be the best catalyst. It should be noted that in the absence of Lewis acid, **1a** reacts very slowly with NBS, CH₃CN, and TMSN₃, and after 12 h, a mixture of 1,2-bromotetrazole **2a**, bromoazide **3a**, and dibromide **4a** (1:1:1) was obtained (Table 1, entry 1). When substrate **1a** was treated with 0.05 equiv of Zn(OTf)₂, 1.2 equiv of NBS, 1.5 equiv of TMSN₃, and 4 Å MS in CH₃-CN at rt (25 °C), within 10 min, tetrazole **2a** was selectively obtained in 87% yield (entry 7). It is worth mentioning that presence of 4 Å MS in the reaction medium inhibits the formation of undesired halohydrin compounds.

This method could produce an enormous number of 1,5-disubstituted tetrazoles, if different combinations of alkenes and nitriles are reacted. Initially, a variety of alkenes were subjected to the catalytic reaction in CH₃CN and selectively produced tetrazoles **2** (R³ = CH₃; Table 2) with *anti*-stereochemistry as revealed by the ¹H NMR of the crude products. Reaction of α,β -unsaturated carbonyl compound methyl *p*-methoxycinnamate **1g** under the same reaction conditions also afforded tetrazole **2g** in 12% yield along with the bromoazide **3g** as a major product (entry 6).

Similarly, reactions of different alkenes independently with benzonitrile and benzylcyanide under the same reaction conditions (i.e., using nitrile as a solvent) gave tetrazoles in moderate to good yields (Table 3). Use of excess nitriles could be avoided when TMSN $_3$ in CH $_2$ Cl $_2$ was slowly added over 1-2 h to the solution of Zn(OTf) $_2$ (0.05 equiv), alkene (1.0 equiv), NBS (1.2 equiv), nitrile (5 equiv), and 4 Å MS in CH $_2$ Cl $_2$ and afforded the tetrazoles in comparable yields.

We also investigated the intramolecular reaction of substrate 5. When 5 was subjected to the $Zn(OTf)_2$ catalyzed reaction with NBS, TMSN₃ and 4 Å MS in CH_2Cl_2 , it produced exclusively bromoazide 8, no cyclic fused tetrazole 6 or 7 was obtained (Scheme 1). The reaction of 5 was also carried out in CH_3CN instead of CH_2Cl_2 under the same reaction conditions and afforded the tetrazole 9; here also, no cyclic fused tetrazole 6 or 7 was obtained (Scheme 1).

The synthesis of 1,5-disubstituted tetrazoles via halogenpromoted reaction of alkenes, nitriles, and azide is thought to

TABLE 2. Synthesis of 5-Methyltetrazoles via Zn(OTf)₂-Catalyzed Reaction of Alkenes, NRS, CH₂CN, and TMSN₃

entry	alkene	t (min)	product	yield' (%)
1	1b	20	N, N, N	80
2	le	20	N-N N'N (±)-2c	85
3	1d	30	N-N N-N Br (±)-2d	92
4	le	20	N-N N-N N-N (±)-2e	64
5	1f	30	N-N N'N Br(±)-2f	55
6	MeO OMe	60	N-N N-N OMe	12 ^b
			(±)-2g	

 a Isolated yields of tetrazoles 2 after column chromatography. b Obtained along with 60% of bromoazide 3g.

proceed via nucleophilic¹⁴ opening of halonium ion **10** with R³-CN followed by reaction of the generated nitrilium ion **11** with azide to produce the tetrazole **2** (route a; Scheme 2).¹² Tetrazole **2** might have been produced via nucleophilic ring opening of the bromonium ion **10** by pregenerated tetrazole¹⁵ (route b). However, no tetrazole was produced in the absence of either alkene or NBS or both under the same reaction conditions.

(15) Ek, F.; Wistrand, L.-G.; Frejd, T. Tetrahedron 2003, 59, 6759-6769.

⁽¹⁴⁾ Three-membered halonium ions are also easily opened by a variety of nucleophiles. (a) House, H.O. Modern Synthetic Reaction, 2nd ed.; W. A. Benjamin, Inc.: Menlo Park, 1972; pp 422-446. (b) March, J. Advanced Organic Chemistry, 4th ed.; Wiley: New York, 1992; pp 812-819. (c) Carey, F.; Sundberg, R. Advanced Organic Chemistry, 4th ed.; Plenum Press: New York, 2001; Part B, pp 200-216. (d) Larock, R. C. Comprehensive Organic Transformations, 2nd ed.; Wiley-VCH: New York, 2001; pp 629-633, 638-646. Some selected references: (e) Raghavan, S.; Tony, K. A. Tetrahedron Lett. 2004, 45, 2639-2641. (f) Raghavan, S.; Tony, K. A. J. Org. Chem. 2003, 68, 5002-5004. (g) Cardillo, G.; Gentilucci, L.; Mohr, G. P. Eur. J. Org. Chem. 2001, 3545-3551. (h) Quaglia, W.; Pigini, M.; Tayebati, S. K.; Piergentili, A.; Giannella, M.; Marucci, G.; Melchiorre, C. J. Med. Chem. 1993, 36, 1520-1528. (i) Kumar, R.; Wiebe, L. I.; Hall, T. W.; Knaus, E. E.; Tovell, D. R.; Tyrrell, D. L.; Allen, T. M.; Fathi-Afshar, R. J. Med. Chem. 1989, 32, 941-944. (j) Hudlicky, T.; Radesca, L.; Rigby, H. L. J. Org. Chem. 1987, 52, 4397-4399. (k) Karl, Pfister, K.; C. A. Robinson, C. A.; Shabica, A. C.; Tishler, M. J. Am. Chem. Soc. 1949, 71, 1096-1101. (1) Reference 13 and references therein.

TABLE 3. Synthesis of 5-Phenyl- and 5-Benzyltetrazoles via $Zn(OTf)_2$ -Catalyzed Reaction of Alkenes with NBS, R^3CN ($R^3=Ph, PhCH_2$), and $TMSN_3$

PhCH ₂), and TMSN ₃						
entry	alkene	R ³ CN	t (min)	product	yield ^a (%)	
1	1a	PhCN	60	N-N N'N Br(±)-2h	52	
2	1b	PhCN	60	N, N, N	64	
3	1c	PhCN	60	N-N N-N N-N (±)-2j	62	
4	1d	PhCN	60	N-N N-N Br (±)-2k	68	
				(±)-2N		
5	1e	PhCN	60	N-N N-N N-N N-N (±)-21	52	
6	1a	PhCH ₂ CN	30	N-N N-N N-N Br(±)-2m	56	
7	1b	PhCH ₂ CN	30	N. N	60	
8	1d	PhCH ₂ CN	60	N-N N-N N-N N-N Br	58	
				(±)-2o		

 a Isolated yields of tetrazoles **2** after column chromatography. Obtained along with 10-20% of bromoazide **3**.

Alternatively, initial formation of intermediate compound bromoazide $\bf 3$ followed by [3+2] cycloaddition reaction with nitriles might produce the tetrazole $\bf 2$ (route c). When a solution of pure bromoazide $\bf 3a$ in CH₃CN was stirred in the presence of Zn(OTf)₂ catalyst under the same reaction conditions, even after 10 h it did not yield any tetrazole $\bf 2a$. Thus, it can be

SCHEME 1

SCHEME 2

$$R^3$$
CN + TMSN₃
 R^3 CN + TMSN₃
 R^3
 R^3

SCHEME 3

concluded that the reaction might proceed via nitrilium ion 11 followed by reaction with azide as proposed by Hassner¹² (Scheme 2). The failure of the intramolecular reaction of 5 that may be due to excessive strain in the required six/sevenmembered cyclic nitrilium ion intermediate also supports to the likelihood of a nitrilium ion intermediate 11.

For further structural elaboration, tetrazoles 2a and 2d were separately treated with NaN₃ in DMF and R'SNa (R' = Et, Ph) in MeOH (Scheme 3). However, it produced exclusively eliminated product 13 in high yield, no nucleophilic substituted product 12 was obtained. Eliminated product 13 was also obtained (92%) on reaction with NaOH in MeOH. n-Bu₃SnH mediated reduction of tetrazoles 2a and 2d smoothly provided compounds 14a and 14b in 89% and 75% yields, respectively (Scheme 3).

In summary, we have developed an efficient one-pot stereoselective method for the synthesis of 1,5-disubstituted tetrazoles by metal triflate catalyzed one-pot reaction of alkenes, NBS, nitriles, and $TMSN_3$. Among the metal triflates, $Zn(OTf)_2$ was

found to be the best catalyst. Use of different combinations of alkenes and nitriles produces a variety of 1,5-disubstituted tetrazoles containing an additional α-bromo functionality on the N1-substituent.

Experimental Section

General Procedure for the Synthesis of 1,5-Disubstituted Tetrazoles 2. To a well-stirred suspension of MS 4 Å (0.100 g) and Zn(OTf)₂ (0.009 g, 0.025 mmol) in dry R³CN (1.0 mL) were successively added alkene 1 (0.50 mmol), TMSN₃ (0.1 mL, 0.75 mmol), and NBS (0.107 g, 0.60 mmol) under argon atmosphere at rt (25 °C). The reaction was monitored by TLC. On completion, it was quenched with saturated aqueous NaHCO3 and extracted with CH₂Cl₂ (3 × 30 mL). The combined organic layers were washed with water (25 mL) and brine (25 mL), dried over Na₂SO₄, and concentrated under vacuum. Flash column chromatography purification of the crude material using petroleum ether (60-80 °C)/ ethyl acetate as an eluent afforded the pure tetrazole 2. It is to be noted that quenching the reaction with aqueous solution is to be taken care as TMSN₃ is unstable near moisture with the generation of hydrazoic acid, an extremely dangerous product.

1-(2-Bromo-1,2-diphenylethyl)-5-methyl-1H-tetrazole ((\pm)-**2d):** white solid; mp 185–186 °C; FTIR (KBr) 3034, 2969, 2923, 2361, 2343, 1630, 1525, 1494, 1455, 1391, 1117, 1093, 773, 723, 705, 658, 569, 529 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.65– 7.74 (m, 2H), 7.36-7.52 (m, 4H), 7.21-7.34 (m, 4H), 5.87 (d, $J = 11.1 \text{ Hz}, 1\text{H}, 5.66 \text{ (d, } J = 11.1 \text{ Hz}, 1\text{H}), 2.28 \text{ (s, 3H)}; ^{13}\text{C}$ NMR (50 MHz, CDCl₃/DMSO- $d_6 = 10:1$) δ 150.7, 137.3, 135.2, 129.5, 129.2, 128.9 (2C), 128.8 (2C), 128.2 (2C), 127.4 (2C), 67.9, 52.8, 8.5. Anal. Calcd for C₁₆H₁₅BrN₄: C, 55.99; H, 4.41; N, 16.32. Found: C, 55.78; H, 4.28; N, 16.35.

1-(2-Bromo-1,2-diphenylethyl)-5-phenyl-1H-tetrazole ((\pm)-**2k):** white solid; mp 160–162 °C; FTIR (KBr) 3062, 1611, 1493, 1468, 1454, 1391, 1119, 1101, 1075, 774, 742, 721, 698, 668, 579, 520 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.77–7.82 (m, 2H), 7.45-7.63 (m, 6H), 7.10-7.26 (m, 7H), 5.80 (s, 2H); ¹³C NMR $(50 \text{ MHz}, \text{CDCl}_3) \delta 154.6, 137.0, 135.5, 131.4, 129.7, 129.1 (4C),$ 129.0 (3C), 128.8 (2C), 128.6 (2C), 127.6 (2C), 123.5, 68.1, 53.8. Anal. Calcd for C₂₁H₁₇BrN₄: C, 62.23; H, 4.23; N, 13.82. Found: C, 62.18; H, 4.21; N, 13.63.

5-Benzyl-1-(2-bromo-1,2-diphenylethyl)-1*H*-tetrazole ((\pm)-**20):** white solid; mp 177–178 °C; FTIR (KBr), 3068, 3033, 2929, 1509, 1494, 1455, 1431, 1417, 1233, 1110, 1078, 773, 732, 723, 706, 697, 658, 636, 619, 584, 564, 528 cm⁻¹; ¹H NMR (200 MHz, CDCl₃) δ 7.26–7.37 (m, 8H), 7.15–7.25 (m, 5H), 6.96–7.05 (m, 2H), 5.80 (d, J = 11.1 Hz, 1H), 5.55 (d, J = 11.1 Hz, 1H), 4.04 (d, J = 16.2 Hz, 1H), 3.82 (d, J = 16.2 Hz, 1H); ¹³C NMR (50 MHz, CDCl₃) δ 153.0, 137.4, 135.2, 133.5, 129.5, 129.4 (2C), 129.1, 128.9 (2C), 128.8 (2C), 128.7 (2C), 128.3 (2C), 127.8, 127.6 (2C), 68.0, 53.2, 29.3. Anal. Calcd for C₂₂H₁₉BrN₄: C, 63.02; H, 4.57; N, 13.36. Found: C, 63.29; H, 4.64; N, 13.29.

Acknowledgment. We thank DST (SR/S1/OC-13/2004), New Delhi, for providing financial support and Professor D. Mal for the helpful discussions. D.S. and M.B. thank CSIR, New Delhi, and IIT, Kharagpur, respectively, for their fellow-

Supporting Information Available: Spectral data and ¹H NMR, ¹³C NMR, and DEPT spectra for all compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

JO062432J